Endeavor

CAR T Effective as First-Line Therapy for High-Risk Lymphoma Patients

New three-year data from the phase 2 ZUMA-12 trial finds durable responses

New Study Shows Promise in Equalizing Outcomes for Transplant Patients

Post-transplant drug has potential to close racial gap for mismatched donors

Identifying Inflammatory Markers Related to Toxicities Early Can Improve Multiple Myeloma Treatment

Understanding the immune landscape of CAR T-related toxicities and responses can improve outcomes

CancerX Partnership Tackles Disparities and Financial Toxicity in Cancer Care and Research

Launched in 2023, CancerX is part of the White House Cancer Moonshot initiative

Already Approved Drug Shows Promise in Patients with MDS/MPN Overlapping Syndromes

Moffitt launched trial investigates myelofibrosis drug in rare patient population

Looking at Guided Radiation for Triple-Negative Breast Cancer

A new study personalizes radiation therapy doses for patients based on their tumor profile

Using Contemporary Data to Better Classify Blood Clot Risk in Polycythemia Vera Patients

Study shows age is less of a factor than medical history when it comes to risk for thrombosis

The Creation of Bioengineering at Moffitt

Groundbreaking department brings new tools and fresh perspectives to the fight against cancer

Miles for Moffitt Sets Record-Breaking Numbers

More than $1.6 million raised with 9,500 participants and 430 teams